3 insiders at Inhibrx Biosciences Inc. (INBX) reported open-market stock purchases totaling $3,499,597 in recent weeks, according to filings with the U.S. Securities and Exchange Commission. The largest reported purchase came from Lappe Mark (director, officer: Chief Executive Officer), who acquired 9,681 shares at $112.28 on September 08, 2026.
Source: SEC Form 4. Option grants and tax-withholding sales are excluded.
| Date | Insider | Role | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|
| 2026-09-08 | Kayyem Jon Faiz | director | 5,000 | $113.52 | $567,580 | SEC Form 4 |
| 2026-09-08 | FORSYTH DOUGLAS | director | 2,500 | $114.65 | $286,617 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 9,681 | $112.28 | $1,087,001 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 1,219 | $111.88 | $136,382 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 500 | $108.23 | $54,118 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 1,100 | $107.12 | $117,836 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 6,605 | $100.64 | $664,719 | SEC Form 4 |
| 2026-09-08 | Lappe Mark | director, officer: Chief Executive Officer | 5,895 | $99.29 | $585,343 | SEC Form 4 |
Inhibrx Biosciences Inc. is a Healthcare company in the Biotechnology industry. It carried a market capitalization of about $1.7B, with shares trading near $114.34.
This article is automated factual reporting of public SEC filings, for informational purposes only. It is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security, and reflects no opinion on the company. Figures are drawn from filings believed reliable but are not guaranteed. Always verify against the primary SEC filing and consult a licensed professional. Investing can lose value, up to total loss.